NCT01403025View on ClinicalTrials.gov

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

CompletedOBSERVATIONAL
Enrollment

4,121

Participants

Timeline

Start Date

July 19, 2011

Primary Completion Date

December 28, 2015

Study Completion Date

December 28, 2015

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm

Trial Locations (1)

1000005

Novo Nordisk Investigational Site, Tokyo

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY